贝瑞基因
(000710)
| 流通市值：30.90亿 | | | 总市值：32.56亿 |
| 流通股本：3.36亿 | | | 总股本：3.54亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 676,598,645.04 | 446,766,809.76 | 210,215,582.68 | 929,818,022.06 |
| 营业收入 | 676,598,645.04 | 446,766,809.76 | 210,215,582.68 | 929,818,022.06 |
| 二、营业总成本 | 717,441,912.89 | 462,287,478.74 | 217,562,649.71 | 1,009,161,258.53 |
| 营业成本 | 354,528,373.58 | 221,005,957.24 | 101,989,226.46 | 528,602,652.28 |
| 税金及附加 | 3,594,507.41 | 2,411,776.65 | 483,749.8 | 5,506,633.49 |
| 销售费用 | 159,688,778.33 | 102,854,703.2 | 50,961,801.16 | 206,473,928.91 |
| 管理费用 | 113,820,827.66 | 80,171,067 | 38,992,651.17 | 157,752,381.05 |
| 研发费用 | 84,265,671.17 | 54,752,595 | 24,412,392.8 | 104,363,779.56 |
| 财务费用 | 1,543,754.74 | 1,091,379.65 | 722,828.32 | 6,461,883.24 |
| 其中:利息费用 | 5,579,467.46 | 4,151,554 | 1,949,508.01 | 9,979,243.93 |
| 其中:利息收入 | -1,240,658.93 | 785,092.48 | -405,425.98 | 3,196,609.04 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | -2,841,154.08 |
| 加:投资收益 | -1,109,043.02 | -645,647.25 | -924,712.99 | -3,537,842.81 |
| 资产处置收益 | -817,132.57 | -1,884,589.29 | -842,035.43 | 4,998,568.37 |
| 资产减值损失(新) | - | - | - | 674,124.35 |
| 信用减值损失(新) | -46,979,203.04 | -20,745,795.48 | -10,320,279.5 | -108,982,571.91 |
| 其他收益 | 2,882,173.75 | 2,081,635.42 | 1,736,944.19 | 1,696,521.51 |
| 四、营业利润 | -86,866,472.73 | -36,715,065.58 | -17,697,150.76 | -187,335,591.04 |
| 加:营业外收入 | 911,251.6 | 717,828.61 | 158,701.44 | 4,005,221.05 |
| 减:营业外支出 | 6,113,088.09 | 179,347.05 | 44,366.84 | 6,225,796.07 |
| 五、利润总额 | -92,068,309.22 | -36,176,584.02 | -17,582,816.16 | -189,556,166.06 |
| 减:所得税费用 | 8,753,608.05 | 6,940,112.53 | 1,486,615.21 | 6,737,971.96 |
| 六、净利润 | -100,821,917.27 | -43,116,696.55 | -19,069,431.37 | -196,294,138.02 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -100,821,917.27 | -43,116,696.55 | -19,069,431.37 | -196,294,138.02 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -102,470,036.09 | -43,947,875.05 | -19,738,153.1 | -196,838,894.41 |
| 少数股东损益 | 1,648,118.82 | 831,178.5 | 668,721.73 | 544,756.39 |
| 扣除非经常损益后的净利润 | -102,688,270.3 | -48,140,019.55 | -19,707,266.42 | -206,498,039.43 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.29 | -0.12 | -0.06 | -0.56 |
| (二)稀释每股收益 | -0.29 | -0.12 | -0.06 | -0.56 |
| 八、其他综合收益 | -26,726,554.25 | -7,132,745.91 | -4,233,147.77 | -5,649,446.76 |
| 归属于母公司股东的其他综合收益 | -10,193,768.16 | -5,828,137.99 | -3,481,034.08 | -4,691,843.02 |
| 九、综合收益总额 | -127,548,471.52 | -50,249,442.46 | -23,302,579.14 | -201,943,584.78 |
| 归属于母公司股东的综合收益总额 | -112,663,804.25 | -49,776,013.04 | -23,219,187.18 | -201,530,737.43 |
| 归属于少数股东的综合收益总额 | -14,884,667.27 | -473,429.42 | -83,391.96 | -412,847.35 |
| 公告日期 | 2026-10-27 | 2026-08-24 | 2026-04-30 | 2026-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |